the present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis b virus antigen , which formulations exhibit stability , low to undetectable levels of aggregations , and very little to no loss of the biological activities of the antibodies or antibody fragments , even during long periods of storage . furthermore , the invention provides methods of preventing , treating or ameliorating one or more symptoms associated with hbv infection utilizing the liquid formulations of the present invention .